ONCS Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 1.32%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
OncoSec Medical Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 06/23/2023 05:00 PM ET
OncoSec Medical Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/9/2023 | Robert J. DelAversano | VP | Sell | 40 | $1.37 | $54.80 | 1,008 |  |
OncoSec Medical Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 4/12/2023 | FNY Investment Advisers LLC | 105,690 | $0.27M | 0.3% | N/A | 3.559% |  |
| 2/8/2023 | Salzhauer Michael | 20,799 | $35K | 0.0% | -93.0% | 0.700% | |
| 5/10/2022 | Salzhauer Michael | 296,282 | $0.34M | 0.2% | -7.8% | 0.753% | |
| 4/13/2022 | Sandbox Financial Partners LLC | 27,500 | $32K | 0.0% | -56.0% | 0.070% | |
| 2/14/2022 | Long Focus Capital Management LLC | 69,226 | $66K | 0.0% | N/A | 0.176% | |
| 2/4/2022 | Salzhauer Michael | 321,354 | $0.31M | 0.1% | +15.9% | 0.817% | |
| 1/31/2022 | D.A. Davidson & CO. | 57,500 | $55K | 0.0% | -47.0% | 0.146% | |
| 11/16/2021 | Schonfeld Strategic Advisors LLC | 25,400 | $55K | 0.0% | -28.0% | 0.065% | |
| 11/16/2021 | Two Sigma Advisers LP | 361,401 | $0.77M | 0.0% | +128.2% | 0.922% | |
| 11/15/2021 | Tocqueville Asset Management L.P. | 49,500 | $0.11M | 0.0% | +86.8% | 0.126% | |
| 11/15/2021 | HighTower Advisors LLC | 20,705 | $45K | 0.0% | N/A | 0.053% | |
| 8/16/2021 | State Street Corp | 19,929 | $56K | 0.0% | N/A | 0.051% | |
Data available starting January 2016
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Read More on OncoSec Medical
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
52,491,000 shs
Average Volume
2,219,449 shs
Market Capitalization
$1.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.99
